Evidence map›Paper›PMID 42701122›Full record

ArticleBritish journal of cancer2026

Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus-associated oropharyngeal cancer: a multicentre Phase II trial.

Tomoya Yokota, Toyonori Tsuzuki, Tetsuro Onitsuka, Akira Iizuka, Yohei Ouchi, Terushige Mori, Kiyoaki Tsukahara, Kenji Hanyu, Takashi Mukaigawa, Torahiko Nakashima and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tomoya YokotaDepartment of Head and Neck Medical Oncology, Shizuoka Cancer Center, Sunto-gun, Japan. t.yokota@scchr.jp.ORCID http://orcid.org/0000-0001-7327-7949
Toyonori TsuzukiDepartment of Surgical Pathology, Aichi Medical University, Nagakute, Japan.ORCID http://orcid.org/0000-0002-4855-4366
Tetsuro OnitsukaDepartment of Head and Neck Surgery, Mishima Central Hospital, Mishima, Japan.
Akira IizukaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Japan.
Yohei OuchiDepartment of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Japan.
Terushige MoriDepartment of Otolaryngology, Faculty of Medicine, Kagawa University, Kita-gun, Japan.
Kiyoaki TsukaharaDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Kenji HanyuDepartment of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
Takashi MukaigawaDivision of Head and Neck Surgery, Shizuoka Cancer Center, Sunto-gun, Japan.
Torahiko NakashimaDepartment of Otorhinolaryngology Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Hideoki UryuDepartment of Otorhinolaryngology Head and Neck Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Go OmuraDepartment of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan.
Hiromu NakamuraOtolaryngology-Head and Neck Surgery, Aichi Medical University, Nagakute, Japan.
Hirokazu UemuraDepartment of Otolaryngology-Head and Neck Surgery, Nara Medical University, Kashihara, Japan.
Daisuke NishikawaDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Satoshi KanoDepartment of Otolaryngology-Head and Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Yasuto AkiyamaImmunotherapy Division, Shizuoka Cancer Center Research Institute, Sunto-gun, Japan.
Tsuyoshi OnoeDivision of Radiation Oncology, Shizuoka Cancer Center, Sunto-gun, Japan.
Shunsuke OyamadaDepartment of Biostatistics, JORTC Data Center, Tokyo, Japan.
Takuhiro YamaguchiDivision of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.

Funding

Japan Agency for Medical Research and Development (AMED) 22ck0106767h0001
6 · The paper itself

Abstract

backgroundThis prospective Phase 2 trial assessed a novel de-escalation strategy for upfront neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (NAC-TPF) to avoid postoperative radiotherapy (PORT) and chemoradiotherapy (POCRT) for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).

methodsPatients with HPV-associated resectable OPSCC were enrolled. Invasive surgery or PORT/POCRT was an inclusion criterion if upfront surgery was performed. Treatment started with three cycles of NAC-TPF, followed by surgery. The primary endpoint was the centrally reviewed pathological complete response (pCR) rate after NAC-TPF. Levels of high-risk HPV RNA in tumor specimens and plasma circulating tumor (ct) HPV DNA, and quality of life (QOL) scores were assessed.

resultsOf 32 eligible patients, 30 patients underwent transoral surgery after NAC-TPF. R0 resection was confirmed in 31 patients. pCR and virological complete response rate at both the primary site and lymph nodes were 65.6% and 64.5%, respectively. No PORT/POCRT was performed in 91%. All QOL scores recovered to baseline values or improved within 1 year. Twenty-three patients showed undetectable ctHPV DNA levels after NAC-TPF.

conclusionAlthough the primary endpoint was not met, NAC-TPF in HPV-associated resectable OPSCC achieved clinically meaningful pCR, enabling avoidance of PORT/POCRT in the majority of patients. (Clinical trial registration numbers: jRCT1041220029).

Identifiers

PMID42701122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.